UY26975A1 - Inhibición de la dependencia de células tumorales del factor de crecimiento. - Google Patents

Inhibición de la dependencia de células tumorales del factor de crecimiento.

Info

Publication number
UY26975A1
UY26975A1 UY26975A UY26975A UY26975A1 UY 26975 A1 UY26975 A1 UY 26975A1 UY 26975 A UY26975 A UY 26975A UY 26975 A UY26975 A UY 26975A UY 26975 A1 UY26975 A1 UY 26975A1
Authority
UY
Uruguay
Prior art keywords
growth factor
tumor cells
dependency
inhibition
dependence
Prior art date
Application number
UY26975A
Other languages
English (en)
Inventor
Rosemarie Lichtner
Ulrike Fuhrmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY26975A1 publication Critical patent/UY26975A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención se refiere al uso de inhibidores del receptor de progesterona para inhibir la dependencia de las células tumorales, del factor de crecimiento.
UY26975A 2000-10-18 2001-10-17 Inhibición de la dependencia de células tumorales del factor de crecimiento. UY26975A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10051609A DE10051609A1 (de) 2000-10-18 2000-10-18 Hemmung der Wachstumsfaktorabhängigkeit von Tumorzellen

Publications (1)

Publication Number Publication Date
UY26975A1 true UY26975A1 (es) 2002-06-20

Family

ID=7660193

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26975A UY26975A1 (es) 2000-10-18 2001-10-17 Inhibición de la dependencia de células tumorales del factor de crecimiento.

Country Status (10)

Country Link
US (1) US20040157811A1 (es)
AR (1) AR034562A1 (es)
DE (1) DE10051609A1 (es)
EC (1) ECSP034604A (es)
PE (1) PE20020472A1 (es)
PT (1) PT1414465E (es)
TW (1) TWI234458B (es)
UY (1) UY26975A1 (es)
YU (1) YU30003A (es)
ZA (1) ZA200303785B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
US20080261933A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with a lutein-hormone-releasing hormone agonist and antagonist for use in brca mediated diseases
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238950A (en) * 1991-12-17 1993-08-24 Schering Corporation Inhibitors of platelet-derived growth factor
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette

Also Published As

Publication number Publication date
PE20020472A1 (es) 2002-06-15
AR034562A1 (es) 2004-03-03
DE10051609A1 (de) 2002-05-02
ECSP034604A (es) 2003-06-25
ZA200303785B (en) 2005-08-29
TWI234458B (en) 2005-06-21
PT1414465E (pt) 2007-01-31
YU30003A (sh) 2006-08-17
US20040157811A1 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
HN2001000217A (es) Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
MXPA03001511A (es) Imidazol-5-il-2-amino-pirimidinas como agentes para la inhibicion de la proliferacion celular.
HN2003000285A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
CR8357A (es) Derivados de tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorio
EA200300105A1 (ru) Нестероидные ингибиторы воспалений
CY1106289T1 (el) Χρηση αναστολεων υποδοχεος προγεστepονης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου που ειναι ανθεκτικος σε στepοειδη
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
BR0007864A (pt) Composto, e, uso de um composto
UY26975A1 (es) Inhibición de la dependencia de células tumorales del factor de crecimiento.
SV2006002220A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios ref. p-sv-78.836/cd
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
BR0307903A (pt) derivados de arilsulfona
BR0116152B1 (pt) aditivo adequado para uso como emulsificador e solubilizador, uso de um aditivo, e, composição.
DK1212311T3 (da) Chalconcumariner
SV2002000041A (es) Derivados de resorcinol ref. pc10529/82897/bb
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
ATE259886T1 (de) Ledergerben
DK1177191T3 (da) Substituerede benzimidazoler, fremstilling og anvendelse deraf som midler til bekæmpelse af parasitiske protozoer
PE20020511A1 (es) Uso de antiprogestinas para la induccion de apoptosis en una celula
PT1194158E (pt) Uso da proteina uk 114 para inibir a rejeicao do transplante de orgaos
UY26893A1 (es) Combinación farmacéutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversión de la angiotensina i
ECSP003440A (es) Nuevos compuestos de pirimidinona y procedimiento
ECSP003651A (es) Nuevos compuestos espiroheterociclicos utiles como inhibidores reversibles de cisteina-proteasas
HN2002000177A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso.
GT199900178A (es) Metodo para utilizar inhibidores de la enzima ciclooxigenasa-2 en la prevencion de trastornos cardiovasculares.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150513